Evidence map›Paper›PMID 27987372›Full record

ArticleCancer science2017

SIX1 maintains tumor basal cells via transforming growth factor-β pathway and associates with poor prognosis in esophageal cancer.

Takao Nishimura, Masashi Tamaoki, Rie Komatsuzaki, Naohide Oue, Hirokazu Taniguchi, Masayuki Komatsu, Kazuhiko Aoyagi, Keiko Minashi, Fumiko Chiwaki, Hisashi Shinohara and 6 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. All eyes on Eya: A unique transcriptional co-activator and phosphatase in cancer.Biochimica et biophysica acta. Reviews on cancer · 2024
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Metabolism and immunity in breast cancer.Frontiers of medicine · 2021
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Takao NishimuraDepartment of Translational Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Masashi TamaokiDepartment of Translational Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Rie KomatsuzakiDepartment of Translational Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Naohide OueDepartment of Molecular Pathology, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima, Japan.
Hirokazu TaniguchiDepartment of Pathology, National Cancer Center Hospital, Tokyo, Japan.
Masayuki KomatsuDepartment of Translational Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Kazuhiko AoyagiDepartment of Translational Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Keiko MinashiDepartment of Clinical Trial Promotion, Chiba Cancer Center, Chiba, Japan.
Fumiko ChiwakiDepartment of Translational Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Hisashi ShinoharaDepartment of Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yuji TachimoriDepartment of Esophageal Surgery, National Cancer Center Hospital, Tokyo, Japan.
Wataru YasuiDepartment of Molecular Pathology, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima, Japan.
Manabu MutoDepartment of Therapeutic Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Teruhiko YoshidaDivision of Genetics, National Cancer Center Research Institute, Tokyo, Japan.
Yoshiharu SakaiDepartment of Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Hiroki SasakiDepartment of Translational Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Kyoto University · JPHiroshima University · JPChiba Cancer Center · JPNational Cancer Centre Japan · JPTokyo National Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Esophageal squamous cell carcinoma (ESCC) is one of the most common malignant tumors. Although improvement in both surgical techniques and neoadjuvant chemotherapy has been achieved, the 5-year survival rate of locally advanced tumors was, at best, still 55%. Therefore, elucidation of mechanisms of the malignancy is eagerly awaited. Epithelial-mesenchymal transition (EMT) by transforming growth factor-β (TGF-β) has been reported to have critical biological roles for cancer cell stemness, whereas little is known about it in ESCC. In the current study, a transcriptional factor SIX1 was found to be aberrantly expressed in ESCCs. SIX1 cDNA transfection induced overexpression of transforming growth factors (TGFB1 and TGFB2) and its receptor (TGFBR2). Cell invasion was reduced by SIX1 knockdown and was increased in stable SIX1-transfectants. Furthermore, the SIX1-transfectants highly expressed tumor basal cell markers such as NGFR, SOX2, ALDH1A1, and PDPN. Although mock-transfectants had only a 20% PDPN-high population, SIX1-transfectants had 60-70%. In two sets of 42 and 85 ESCC patients receiving surgery alone or neoadjuvant chemoradiotherapy followed by surgery, the cases with high SIX1 mRNA and protein expression level significantly showed a poor prognosis compared with those with low levels. These SIX1 high cases also expressed the above basal cell markers, but suppressed the differentiation markers. Finally, TGF-β signaling blockade suppressed ESCC cell growth in association with the reduction of PDPN-positive tumor basal cell population. The present results suggest that SIX1 accelerates self-renewal of tumor basal cells, resulting in a poor prognosis for ESCC patients.

Indexed as

Epithelial-Mesenchymal TransitionCarcinoma, Squamous CellCell Line, TumorEsophageal NeoplasmsHomeodomain ProteinsHumansMembrane GlycoproteinsNeoplasm ProteinsPodoplaninPrognosisReceptors, Transforming Growth Factor betaTransfectionTransforming Growth Factor betaHomeodomain ProteinsMembrane GlycoproteinsNeoplasm ProteinsPDPN protein, humanPodoplaninReceptors, Transforming Growth Factor betaSIX1 protein, humanTransforming Growth Factor betaEpithelial-mesenchymal transitionesophageal cancerprognosisSIX1transforming growth factor-β

Identifiers

PMID27987372
PMCPMC5329162
OpenAlexW2564801645

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.